Actualités

Scott Melker discusses the history and structure of the Federal Reserve and presents bitcoin as a decentralized alternative. “The Daily Wolf with Scott Melker” airs on Yahoo Finance every day at 12:00 p.m. Tune in for your daily dose of all things crypto.Make sure to also check out Yahoo Finance's new crypto hub to find the latest crypto-related news.

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued US Stocks According to Hedge Funds. On May 13, Pfizer Inc. (NYSE:PFE) announced receiving marketing authorization from the European Commission to expand the use of HYMPAVZI (marstacimab) for hemophilia A and B patients aged 12+ who have developed inhibitors. ​Management noted that roughly 20% of hemophilia […]

Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and positive Phase 2 data for its 25 valent pneumococcal vaccine in infants, sparked fresh interest in the stock. See our latest analysis for Pfizer. Despite the HYMPAVZI approval and vaccine pipeline updates, the share price is still around US$25.79, with a 30 day share price return down 6.29% but a 1 year total shareholder return of 19.76%. This suggests recent momentum has...

The market appears to be short-sighted.

Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate vaccine in infants, showing strong immune responses versus PREVNAR 20 and prompting the launch of a pivotal Phase 3 pediatric program. The move to a broader 25‑strain infant vaccine candidate, alongside plans for a fifth‑generation 35‑valent adult vaccine, highlights how Pfizer is aiming to extend its long-standing pneumococcal franchise through higher‑value, next‑generation...

Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer. The agreement follows Phase 3 data that support clinical benefit in a difficult to treat patient group and inclusion of VEPPANU in NCCN breast cancer guidelines. The deal introduces a new commercialization pathway for VEPPANU and adds another partnership driven revenue channel for Pfizer. For investors...

New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.

(Bloomberg) -- Turns out, loading up on technology giants isn’t the only route to better returns. Value companies, too, stand a decent chance of trouncing the market — as long as several conditions are met. Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Threatens Iran With ‘Bi

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

With markets at elevated multiples in May 2026, low share prices can mislead investors into thinking quality is out of reach. Stocks trading below $30 with strong balance sheets offer income, deleveraging stories, or growth at valuations that build in a margin of safety. Here are five stocks trading under $30 that pair solid books ... The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi’s simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For ... Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t

With short-term rates still elevated, tariff uncertainty churning through earnings models, and credit spreads widening at the margins, balance sheet quality has quietly become the most underrated factor in equity selection. Stocks under $30 often get dismissed as broken or speculative, but a handful of large, cash-generative businesses currently trade in that zone with the ... Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

These stocks could look like steals in a few years.

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Honeywell was added to the Dow for its tech focus and diversification across different end markets.

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Management attributed the quarter’s performance to strong partner-driven revenue streams, particularly from milestone payments and supply sales tied to agreements with Sanofi and Pfizer. CEO John Jacobs emphasized the shift from direct commercial activity to a strategy anchored by licensing and collaboration, noting, “We now have either licensing

With an annual dividend yield of 6.68%, Pfizer Inc. (NYSE:PFE) is included among the 10 Best Dividend Stocks with 5%+ Yields and Growing Cash Flows. On May 14, Wolfe Research analyst Alexandria Hammond raised the firm’s price recommendation on Pfizer Inc. (NYSE:PFE) to $26 from $25. It reiterated an Underperform rating on the shares following what the […]

The Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) and the Fundstrat Granny Shots US Large Cap ETF (NYSEARCA:GRNY) sit on opposite ends of how quality gets defined in a large-cap portfolio. COWZ ranks the Russell 1000 by free cash flow yield and takes the top 100 names, a rules-based screen with no human override. GRNY ... GRNY Beat COWZ by 11 Points This Year. Oil Prices and Interest Rates Will Decide Who Wins Next

Pfizer (NYSE:PFE) received European Commission approval to expand HYMPAVZI to adolescents with hemophilia A or B and inhibitors. The decision opens access to a new patient group within the EU hemophilia market for this rare disease therapy. The expanded label highlights bleed protection and a simplified administration regimen for a hard to treat population. For investors watching NYSE:PFE, this update is part of Pfizer's broader push in rare diseases, an area where specialized treatments...

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.

Pfizer (NYSE:PFE) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations. Michael Burry purchased these shares for their real earnings and margin stability, and with inflation still pressuring margins across the market, names that generate cash, hold pricing power, and trade at sober multiples carry a structural ... Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year.

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.